These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
147 related articles for article (PubMed ID: 10966008)
21. Abciximab therapy and unplanned coronary stent deployment: favorable effects on stent use, clinical outcomes, and bleeding complications. EPILOG Trial Investigators. Kereiakes DJ; Lincoff AM; Miller DP; Tcheng JE; Cabot CF; Anderson KM; Weisman HF; Califf RM; Topol EJ Circulation; 1998 Mar; 97(9):857-64. PubMed ID: 9521334 [TBL] [Abstract][Full Text] [Related]
22. Emergency coronary artery bypass grafting in patients with acute myocardial infarction treated with glycoprotein IIb/IIIa receptor inhibitors. De Carlo M; Maselli D; Cortese B; Ciabatti N; Gistri R; Levantino M; Balbarini A; De Caterina R; Petronio AS Int J Cardiol; 2008 Jan; 123(3):229-33. PubMed ID: 17433463 [TBL] [Abstract][Full Text] [Related]
23. Sustained suppression of ischemic complications of coronary intervention by platelet GP IIb/IIIa blockade with abciximab: one-year outcome in the EPILOG trial. Evaluation in PTCA to Improve Long-term Outcome with abciximab GP IIb/IIIa blockade. Lincoff AM; Tcheng JE; Califf RM; Kereiakes DJ; Kelly TA; Timmis GC; Kleiman NS; Booth JE; Balog C; Cabot CF; Anderson KM; Weisman HF; Topol EJ Circulation; 1999 Apr; 99(15):1951-8. PubMed ID: 10208997 [TBL] [Abstract][Full Text] [Related]
24. Initial experience with an intravenous P2Y12 platelet receptor antagonist in patients undergoing percutaneous coronary intervention: results from a 2-part, phase II, multicenter, randomized, placebo- and active-controlled trial. Greenbaum AB; Grines CL; Bittl JA; Becker RC; Kereiakes DJ; Gilchrist IC; Clegg J; Stankowski JE; Grogan DR; Harrington RA; Emanuelsson H; Weaver WD Am Heart J; 2006 Mar; 151(3):689.e1-689.e10. PubMed ID: 16504633 [TBL] [Abstract][Full Text] [Related]
25. Emergency coronary artery bypass grafting (CABG) after failed coronary artery intervention--caution regarding the combined use of aspirin, ticlopidine and abciximab. Alvarez JM; Harper RW; Peverill RE Aust N Z J Med; 1998 Aug; 28(4):463-4. PubMed ID: 9777116 [No Abstract] [Full Text] [Related]
36. More evidence for a beneficial effect of platelet glycoprotein IIb/IIIa-blockade during coronary interventions. Latest results from the EPILOG and CAPTURE trials. van de Werf F Eur Heart J; 1996 Mar; 17(3):325-6. PubMed ID: 8737200 [No Abstract] [Full Text] [Related]
37. Complementary clinical benefits of coronary-artery stenting and blockade of platelet glycoprotein IIb/IIIa receptors. Evaluation of Platelet IIb/IIIa Inhibition in Stenting Investigators. Lincoff AM; Califf RM; Moliterno DJ; Ellis SG; Ducas J; Kramer JH; Kleiman NS; Cohen EA; Booth JE; Sapp SK; Cabot CF; Topol EJ N Engl J Med; 1999 Jul; 341(5):319-27. PubMed ID: 10423466 [TBL] [Abstract][Full Text] [Related]
38. Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions. Best PJ; Lennon R; Gersh BJ; Ting HH; Rihal CS; Bell MR; Herzog CA; Holmes DR; Berger PB Am Heart J; 2003 Aug; 146(2):345-50. PubMed ID: 12891206 [TBL] [Abstract][Full Text] [Related]
39. Abciximab to prevent vessel closure after angioplasty. Med Lett Drugs Ther; 1995 Jun; 37(950):52-3. PubMed ID: 7760769 [No Abstract] [Full Text] [Related]
40. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. Topol EJ; Moliterno DJ; Herrmann HC; Powers ER; Grines CL; Cohen DJ; Cohen EA; Bertrand M; Neumann FJ; Stone GW; DiBattiste PM; Demopoulos L; N Engl J Med; 2001 Jun; 344(25):1888-94. PubMed ID: 11419425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]